|
KMID : 1040620160220030366
|
|
Clinical and Molecular Hepatology
2016 Volume.22 No. 3 p.366 ~ p.371
|
|
|
Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
|
|
Kim Jong-Man
Lee Kwang-Woong
Song Gi-Won
Jung Bo-Hyun
Lee Hae-Won
Yi Nam-Joon
Kwon Choon-Hyuck David
Hwang Shin
Suh Kyung-Suk
Joh Jae-Won
Lee Suk-Koo
Lee Sung-Gyu
|
|
|
Abstract
|
|
|
Background/Aims: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR.
Methods: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers.
Results: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive.
Conclusion: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
|
|
|
KEYWORD
|
|
|
Hepatitis C virus, Immunosuppression, Rejection, Outcome, Calcineurin antagonists, Tacrolimus
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|